Owen R - Search Results

1

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial.

Royle KL, Coulson AB, Ramasamy K, Cairns DA, Hockaday A, Quezada S, Drayson M, Kaiser M, Owen R, Auner HW, Cook G, Meads D, Olivier C, Barnard L, Lambkin R, Paterson A, Dawkins B, Chapman M, Pratt G, Popat R, Jackson G, Bygrave C, Sive J, de Tute R, Chantry A, Parrish C, Cook M, Asher S, Yong K. Royle KL, et al. Among authors: owen r. BMJ Open. 2022 Nov 17;12(11):e063037. doi: 10.1136/bmjopen-2022-063037. BMJ Open. 2022. PMID: 36396306 Free PMC article.

2

B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors.

Rawstron AC, Davies FE, Owen RG, English A, Pratt G, Child JA, Jack AS, Morgan GJ. Rawstron AC, et al. Among authors: owen rg. Br J Haematol. 1998 Jan;100(1):176-83. doi: 10.1046/j.1365-2141.1998.00525.x. Br J Haematol. 1998. PMID: 9450807 Free article.

3

Insertional events as well as translocations may arise during aberrant immunoglobulin switch recombination in a patient with multiple myeloma.

Pratt G, Fenton JA, Davies FE, Rawstron AC, Richards SJ, Collins JE, Owen RG, Jack AS, Smith GM, Morgan GJ. Pratt G, et al. Among authors: owen rg. Br J Haematol. 2001 Feb;112(2):388-91. doi: 10.1046/j.1365-2141.2001.02588.x. Br J Haematol. 2001. PMID: 11167836 Free article.

4

The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.

Davies FE, Forsyth PD, Rawstron AC, Owen RG, Pratt G, Evans PA, Richards SJ, Drayson M, Smith GM, Selby PJ, Child JA, Morgan GJ. Davies FE, et al. Among authors: owen rg. Br J Haematol. 2001 Mar;112(3):814-9. doi: 10.1046/j.1365-2141.2001.02530.x. Br J Haematol. 2001. PMID: 11260088 Free article.

5

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.

Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, Owen RG, Jack AS, Child JA, Morgan GJ. Rawstron AC, et al. Among authors: owen rg. Blood. 2002 Nov 1;100(9):3095-100. doi: 10.1182/blood-2001-12-0297. Blood. 2002. PMID: 12384404 Free article.

6

Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism.

Fenton JA, Pratt G, Rawstron AC, Sibley K, Rothwell D, Yates Z, Dring A, Richards SJ, Ashcroft AJ, Davies FE, Owen RG, Child JA, Morgan GJ. Fenton JA, et al. Oncogene. 2003 Feb 20;22(7):1103-13. doi: 10.1038/sj.onc.1206335. Oncogene. 2003. PMID: 12592397

7

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ; Medical Research Council Adult Leukaemia Working Party. Child JA, et al. N Engl J Med. 2003 May 8;348(19):1875-83. doi: 10.1056/NEJMoa022340. N Engl J Med. 2003. PMID: 12736280 Free article. Clinical Trial.

8

A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma.

de Tute RM, Jack AS, Child JA, Morgan GJ, Owen RG, Rawstron AC. de Tute RM, et al. Among authors: owen rg. Leukemia. 2007 Sep;21(9):2046-9. doi: 10.1038/sj.leu.2404815. Epub 2007 Jul 26. Leukemia. 2007. PMID: 17657223 No abstract available.

9

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.

Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G, Morilla R, Mylin AK, Omedé P, Pellat-Deceunynck C, Perez Andres M, Petrucci M, Ruggeri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C, Spacek M, de Tute RM, Van Valckenborgh E, Weston-Bell N, Owen RG, San Miguel JF, Sonneveld P, Johnsen HE; European Myeloma Network. Rawstron AC, et al. Among authors: owen rg. Haematologica. 2008 Mar;93(3):431-8. doi: 10.3324/haematol.11080. Epub 2008 Feb 11. Haematologica. 2008. PMID: 18268286 Free article.

10

IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14).

Feyler S, O'Connor SJ, Rawstron AC, Subash C, Ross FM, Pratt G, Drayson MT, Ashcroft J, Cook G, Owen RG. Feyler S, et al. Br J Haematol. 2008 Mar;140(5):547-51. doi: 10.1111/j.1365-2141.2007.06969.x. Br J Haematol. 2008. PMID: 18275432 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,212 results

Search Page